A Phase I, Open-Label, Study of the Safety, Tolerability, and Pharmacokinetics of Pazopanib in Combination With Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28-Day Cycle, Paclitaxel and Carboplatin on an Every 21 Days Schedule and Lapatinib and Paclitaxel on a Weekly Schedule for Three Consecutive Weeks of a 28- Day Cycle
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Pazopanib (Primary) ; Carboplatin; Lapatinib; Paclitaxel
- Indications Cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 10 Nov 2009 Actual initiation date changed from May 2006 to Apr 2006 and actual patient number (86) added as reported by ClinicalTrials.gov.
- 10 Nov 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 10 Nov 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.